NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE.
Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known a
Pharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused it of exchanging commercially sensitive information about prices for nortriptylin